Vascular Endothelial Growth Factor Receptor 3 / VEGFR3 (FLT4) Antibody (FITC)
442€ (200 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Vascular Endothelial Growth Factor Receptor 3 / VEGFR3 (FLT4) Antibody (FITC)
category
Primary Antibodies
provider
Abbexa
reference
abx273912
tested applications
WB, IHC, IF/ICC
Description
Vascular Endothelial Growth Factor Receptor 3 / VEGFR3 (FLT4) Antibody (FITC) is a Rabbit Polyclonal antibody conjugated to FITC against Vascular Endothelial Growth Factor Receptor 3 / VEGFR3 (FLT4).
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Vascular Endothelial Growth Factor Receptor 3 / VEGFR3 (FLT4) |
| Host | Rabbit |
| Reactivity | Mouse |
| Recommended Dilution | WB: 0.5-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | FITC |
| Isotype | IgG |
| Purification | Purified by antigen-specific affinity chromatography. |
| Size 1 | 200 µl |
| Size 2 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-15 working days. |
| Storage | Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | PCL,CHTD7,FLT-4,FLT41,LMPH1A,LMPHM1,VEGFR3,VEGFR-3,Tyrosine-protein kinase receptor FLT4,Fms-like tyrosine kinase 4,Vascular endothelial growth factor receptor 3 |
| Background | Antibody anti-FLT4 |
| Status | RUO |
Descripción
Fms related receptor tyrosine kinase 4 (FLT4) FLT4, also known as vascular endothelial growth factor receptor 3 (VEGFR3), is a receptor tyrosine kinase critical for the regulation of lymphangiogenesis, the formation of lymphatic vessels. Structurally, FLT4 comprises an extracellular domain with seven immunoglobulin-like loops, a single transmembrane domain, and an intracellular tyrosine kinase domain. FLT4 binds VEGF-C and VEGF-D ligands, leading to receptor dimerization and activation of downstream signaling pathways, including the MAPK and PI3K-AKT cascades. These pathways are essential for lymphatic endothelial cell proliferation, migration, and survival. FLT4 is predominantly expressed in lymphatic endothelial cells, where it plays a pivotal role in maintaining lymphatic vessel integrity and fluid homeostasis. Dysregulation of FLT4 has been linked to lymphedema, a condition characterized by lymphatic fluid accumulation, and its overexpression has been implicated in cancer progression, where it promotes tumor lymphangiogenesis and metastasis. FLT4 is a promising therapeutic target for modulating lymphatic function in both pathological and developmental contexts.
Related Products
Human FLT4(Vascular endothelial growth factor receptor 3) ELISA Kit
Ver Producto
Mouse VEGFR3/FLT4(Vascular Endothelial Cell Growth Factor Receptor 3) ELISA Kit
Ver Producto